

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.<sup>1</sup>

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**TWELFTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR  
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF  
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE  
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR  
THE PERIOD FROM SEPTEMBER 1, 2020 THROUGH SEPTEMBER 30, 2020**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	September 1, 2020 through September 30, 2020
Monthly Fees Incurred:	\$357,546.50

---

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$0.00

Total Fees and Expenses Due: \$357,546.50

This is a: X monthly \_\_\_\_\_ interim \_\_\_\_\_ final application

**PRIOR APPLICATIONS:**

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$ 299,802.60	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$357,580.40	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$ -	\$ -

Note: The fee examiner's agreed upon reductions of \$30,000 and \$17,500 were allocated evenly across fees from the first and second interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from September 1, 2020 through and including September 30, 2020 (the “**Twelfth Fee Period**”) amount to:

Professional Fees	\$357,546.50
Expenses	<u>0.00</u>
<b>TOTAL</b>	<b><u>\$357,546.50</u></b>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors’ creditors (the “**Allocation Fees**”) and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$286,037.20
Expenses at 100%	<u>0.00</u>
<b>TOTAL</b>	<b><u>\$286,037.20</u></b>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Twelfth Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Twelfth Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Twelfth Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Eleventh Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

#### **NOTICE AND OBJECTION PROCEDURES**

7. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than November 27, 2020 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
8. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
9. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be

preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York  
November 13, 2020

FTI CONSULTING, INC.  
Financial Advisors to the Ad Hoc Committee of  
Governmental and Other Contingent Litigation  
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz  
Matthew Diaz, Senior Managing Director  
Three Times Square, 10<sup>th</sup> Floor  
New York, New York 10036  
Telephone: (212) 499-3611  
Email: matt.diaz@fticonsulting.com

**EXHIBIT A**

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649  
SUMMARY OF HOURS BY PROFESSIONAL  
FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Professional</b>	<b>Position</b>	<b>Specialty</b>	<b>Billing Rate<sup>1</sup></b>	<b>Total Hours</b>	<b>Total Fees</b>
Diaz, Matthew	Senior Managing Director	Restructuring	1,085	78.1	84,738.50
Greenblatt, Matthew	Senior Managing Director	Forensics	985	2.1	2,068.50
Joffe, Steven	Senior Managing Director	Tax	1,125	9.4	10,575.00
Simms, Steven	Senior Managing Director	Restructuring	1,295	2.2	2,849.00
Kyviakidis, Peter	Managing Director	Forensics	765	1.0	765.00
Suric, Emil	Senior Director	Healthcare	820	15.0	12,300.00
Costaldo, Nicole	Senior Director	Forensics	700	1.0	700.00
Bromberg, Brian	Director	Restructuring	815	186.1	151,671.50
Kim, Ye Darm	Senior Consultant	Restructuring	560	127.1	71,176.00
Mazzari, Meredith	Senior Consultant	Forensics	530	0.9	477.00
Kurtz, Emma	Consultant	Restructuring	415	48.4	20,086.00
Hellmund-Mora, Marili	Associate	Restructuring	280	0.5	140.00
<b>GRAND TOTAL</b>				<b>471.8</b>	<b>\$ 357,546.50</b>

1. Reflects blended hourly rates. Billing rates of international professionals have been translated to USD using the relevant spot rate.

**EXHIBIT B****PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY TASK****FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Task Code</b>	<b>Task Description</b>	<b>Total Hours</b>	<b>Total Fees</b>
1	Current Operating Results & Events	9.4	\$ 5,576.00
7	Analysis of Domestic Business Plan	40.7	34,409.50
9	Analysis of Employee Comp Programs	147.4	113,128.00
10	Analysis of Tax Issues	35.7	30,332.50
16	Analysis, Negotiate and Form of POR & DS	19.1	17,413.00
18	Review of Historical Transactions	89.7	66,891.50
19	Case Management	10.5	7,664.50
21	General Meetings with Counsel and/or Ad Hoc Committee	12.8	10,333.00
24	Preparation of Fee Application	25.5	15,242.50
28	Review of IAC Business Plan	81.0	56,556.00
<b>GRAND TOTAL<sup>1</sup></b>		<b>471.8</b>	<b>\$ 357,546.50</b>

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
1	9/1/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/2/2020	Diaz, Matthew	1.4	Review the Debtors' updated operating results.
1	9/2/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/3/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/4/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/8/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/9/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/10/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/11/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/14/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/15/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/16/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/17/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/18/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/21/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/22/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/23/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/24/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/25/2020	Diaz, Matthew	1.1	Review the Debtors' YTD July financial results.
1	9/25/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/28/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/29/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
<b>1 Total</b>			<b>9.4</b>	
7	9/1/2020	Diaz, Matthew	1.3	Review open case items and prepare next steps on the business plan and the IAC workstreams.
7	9/1/2020	Bromberg, Brian	0.9	Follow up on outstanding business plan diligence items with Debtors.
7	9/1/2020	Bromberg, Brian	1.4	Discuss business plan diligence updates with team.
7	9/3/2020	Diaz, Matthew	0.5	Participate in a call with the Company to discuss the proposed Rhodes transaction.
7	9/3/2020	Diaz, Matthew	0.5	Review the updated analysis on the OxyContin forecast.
7	9/3/2020	Diaz, Matthew	0.7	Review the updated OxyContin forecast.
7	9/3/2020	Kim, Ye Darm	0.5	Participate in discussion re: FTI OxyContin forecast and differences from the Debtors forecast.
7	9/3/2020	Kim, Ye Darm	1.1	Review historical OxyContin forecast assumptions prior to call re: revised forecasts.
7	9/3/2020	Kurtz, Emma	0.5	Participate in discussion re: FTI OxyContin forecast and differences from the Debtors forecast.
7	9/3/2020	Bromberg, Brian	0.6	Participate in call with Debtors re: Rhodes Tech.
7	9/3/2020	Bromberg, Brian	0.6	Participate in discussion re: FTI OxyContin forecast and differences from the Debtors forecast.



**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
7	9/3/2020	Suric, Emil	2.8	Prepare for and present on OxyContin due diligence and summary of findings.
7	9/10/2020	Bromberg, Brian	0.5	Review diligence documents re: proposed Rhodes transaction.
7	9/10/2020	Suric, Emil	0.5	Review IPD analytics report re: OxyContin forecasts.
7	9/11/2020	Diaz, Matthew	1.3	Review materials re: proposed Rhodes transaction.
7	9/12/2020	Diaz, Matthew	1.2	Review the proposed Rhodes transaction due diligence materials.
7	9/13/2020	Diaz, Matthew	0.6	Participate in a call with the Debtors and the UCC to discuss the Rhodes transaction.
7	9/18/2020	Bromberg, Brian	0.4	Prepare diligence requests for the updated Debtors' domestic business plan.
7	9/21/2020	Kim, Ye Darm	1.8	Review the Debtors' latest August business plan presentation.
7	9/21/2020	Bromberg, Brian	0.3	Follow up on outstanding business plan diligence items with Debtors.
7	9/21/2020	Bromberg, Brian	1.2	Review new domestic business plan files uploaded to dataroom.
7	9/21/2020	Suric, Emil	0.5	Review Management's responses to questions on OxyContin assumptions and summary to FTI team.
7	9/22/2020	Suric, Emil	0.5	Review IPD analytics report for OxyContin.
7	9/24/2020	Diaz, Matthew	1.3	Review the updated Purdue domestic business plan.
7	9/25/2020	Bromberg, Brian	1.0	Participate in discussion re: OxyContin forecast with team.
7	9/25/2020	Bromberg, Brian	0.7	Follow up on outstanding business plan diligence items with Debtors and counsel.
7	9/25/2020	Suric, Emil	0.5	Review materials on OxyContin to prepare UCC presentation on sensitivities.
7	9/28/2020	Bromberg, Brian	0.5	Coordinate OxyContin forecast call with Debtors.
7	9/28/2020	Suric, Emil	2.9	Conduct OxyContin competitive landscape research.
7	9/28/2020	Suric, Emil	2.8	Prepare OxyContin sensitivity scenario summary and presentation.
7	9/28/2020	Suric, Emil	1.5	Process updates to OxyContin sensitivity Power Point presentation deliverable.
7	9/29/2020	Diaz, Matthew	1.3	Review the OxyContin sensitivity scenarios and related presentation materials.
7	9/29/2020	Kurtz, Emma	0.7	Participate in call re: OxyContin forecast and sensitivity analyses.
7	9/29/2020	Bromberg, Brian	0.7	Review source files for OxyContin forecast and sensitivity scenarios.
7	9/29/2020	Bromberg, Brian	0.5	Review OxyContin forecast slides.
7	9/29/2020	Bromberg, Brian	1.1	Review OxyContin forecast model.
7	9/29/2020	Bromberg, Brian	0.7	Participate in discussion re: OxyContin forecasts with team.
7	9/29/2020	Suric, Emil	2.2	Process additional updates to OxyContin deliverable based on internal discussion.
7	9/29/2020	Suric, Emil	0.8	Participate in internal discussion to prepare for presentation on OxyContin sensitivity analysis and deliverable review.
7	9/30/2020	Diaz, Matthew	0.6	Review the updated OxyContin forecast presentation to the Debtors.
7	9/30/2020	Bromberg, Brian	0.7	Finalize and transmit final OxyContin sensitivity presentation to Debtors.
<b>7 Total</b>			<b>40.7</b>	
9	9/4/2020	Diaz, Matthew	0.5	Participate in call with the Debtors re: the employee compensation plan.
9	9/4/2020	Diaz, Matthew	1.4	Review the proposed updates to the employee compensation plan.
9	9/4/2020	Kim, Ye Darm	0.6	Participate in call with the Debtors re: the employee compensation plan issues.
9	9/4/2020	Kim, Ye Darm	1.2	Review WTW presentation and prior diligence documents re: KEIP KERP and compensation plans.
9	9/4/2020	Kim, Ye Darm	0.5	Participate in internal discussion re: KEIP KERP diligence.
9	9/4/2020	Kim, Ye Darm	3.3	Prepare draft presentation re: KEIP KERP diligence overview.
9	9/4/2020	Kurtz, Emma	0.3	Participate in call re: Debtors' proposed 2020 KEIP and KERP plans.
9	9/4/2020	Bromberg, Brian	0.7	Participate in discussion re: KEIP and KERP with Debtors' counsel.
9	9/4/2020	Bromberg, Brian	1.0	Review KEIP and KERP diligence materials sent by Debtors.
9	9/4/2020	Bromberg, Brian	1.8	Continue review of KEIP and KERP information provided by Debtors.
9	9/4/2020	Bromberg, Brian	0.5	Participate in internal discussion re: KEIP and KERP with team.
9	9/4/2020	Bromberg, Brian	1.3	Continue review of KEIP and KERP diligence documents provided by Debtors.
9	9/5/2020	Bromberg, Brian	2.1	Review and process revisions to presentation on KEIP and KERP.
9	9/5/2020	Bromberg, Brian	3.7	Review supporting data provided for KEIP and KERP compensation figures.
9	9/7/2020	Kim, Ye Darm	1.7	Process revisions to KEIP KERP diligence presentation.
9	9/7/2020	Kim, Ye Darm	2.3	Review Debtor provided KEIP KERP diligence materials.
9	9/7/2020	Bromberg, Brian	0.4	Review latest presentation on KERP KEIP diligence.
9	9/7/2020	Bromberg, Brian	0.5	Correspond with Debtors on KEIP KERP issues.
9	9/8/2020	Diaz, Matthew	1.4	Review the proposed employee compensation programs re: KEIP KERP.
9	9/8/2020	Diaz, Matthew	1.1	Review the latest presentation on the employee compensation plans diligence re: KEIP KERP.
9	9/8/2020	Kim, Ye Darm	1.8	Process updates to KEIP KERP diligence presentation.
9	9/8/2020	Kim, Ye Darm	1.6	Review historical compensation plans for comparable analyses.
9	9/8/2020	Kim, Ye Darm	0.6	Participate in internal meeting re: KEIP/KERP diligence presentation.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
9	9/8/2020	Kim, Ye Darm	2.3	Prepare updated format for KEIP KERP diligence presentation.
9	9/8/2020	Kurtz, Emma	1.0	Participate in call with Debtors to discuss proposed KEIP/KERP plans for 2020.
9	9/8/2020	Bromberg, Brian	1.4	Prepare for call with Debtors on KEIP KERP support files.
9	9/8/2020	Bromberg, Brian	0.8	Participate in discussion re: KEIP KERP deck with team.
9	9/8/2020	Bromberg, Brian	1.8	Review latest presentation on KERP KEIP diligence.
9	9/8/2020	Bromberg, Brian	1.3	Compile question list for Debtors on KEIP KERP issues.
9	9/8/2020	Bromberg, Brian	0.7	Participate in call with Debtors on KERP KEIP plans.
9	9/8/2020	Bromberg, Brian	0.8	Review newly provided answers and support files on KEIP KERP plans.
9	9/9/2020	Diaz, Matthew	1.9	Review the updated employee compensation comparable analysis.
9	9/9/2020	Kim, Ye Darm	2.4	Prepare updates to the KEIP KERP diligence analysis and prepare responses to questions.
9	9/9/2020	Kim, Ye Darm	2.2	Process revisions to KEIP KERP diligence presentation per internal comments.
9	9/9/2020	Bromberg, Brian	1.7	Review updates and provide revisions to presentation on KEIP KERP diligence.
9	9/9/2020	Bromberg, Brian	2.1	Review KEIP and KERP presentation and supporting documents sent by Debtors.
9	9/10/2020	Diaz, Matthew	0.7	Review the UCC's presentation on the employee incentive plans.
9	9/10/2020	Diaz, Matthew	1.0	Participate in call with the UCC's professionals to discuss their opinion on the employee incentive plans.
9	9/10/2020	Diaz, Matthew	2.4	Review the employee compensation plan motion re: KEIP KERP.
9	9/10/2020	Kim, Ye Darm	0.5	Participate in internal discussion re: KEIP KERP diligence analysis.
9	9/10/2020	Kim, Ye Darm	1.5	Process revisions to KEIP KERP diligence presentation.
9	9/10/2020	Bromberg, Brian	0.7	Review UCC presentation on wages diligence re: KEIP KERP.
9	9/10/2020	Bromberg, Brian	0.6	Conduct analysis on wages files provided by Debtors re: KEIP KERP Diligence.
9	9/10/2020	Bromberg, Brian	1.1	Participate in call with UCC advisors on KEIP KERP motion.
9	9/10/2020	Bromberg, Brian	0.8	Review latest changes to presentation re: KEIP KERP diligence.
9	9/10/2020	Bromberg, Brian	0.6	Discuss KEIP KERP motion and related issues with Counsel.
9	9/10/2020	Bromberg, Brian	1.4	Review Debtor responses to KEIP KERP diligence question list.
9	9/11/2020	Diaz, Matthew	2.1	Review of the updated employee comp analysis re: KEIP KERP diligence.
9	9/11/2020	Kim, Ye Darm	2.3	Review KEIP KERP motion and update latest diligence presentation.
9	9/11/2020	Kim, Ye Darm	1.2	Review the UCC's KEIP KERP diligence analysis.
9	9/11/2020	Kim, Ye Darm	0.5	Participate on internal call re: KEIP KERP diligence analysis.
9	9/11/2020	Kim, Ye Darm	0.6	Participate in call with UCC re: UCC analysis of KEIP KERP.
9	9/11/2020	Kim, Ye Darm	3.4	Prepare additional analysis and revisions to the KEIP KERP Diligence presentation.
9	9/11/2020	Bromberg, Brian	0.8	Review comparable KERP KEIP motions for comparison of terms.
9	9/11/2020	Bromberg, Brian	1.3	Participate on internal call re: KEIP KERP diligence analysis.
9	9/11/2020	Bromberg, Brian	2.4	Revise and process updates to KEIP KERP presentation based on commentary.
9	9/11/2020	Bromberg, Brian	2.3	Review KEIP KERP motion and prepare diligence questions for Debtors.
9	9/11/2020	Bromberg, Brian	0.5	Discuss KEIP KERP motion diligence with UCC advisors.
9	9/12/2020	Bromberg, Brian	1.7	Revise and process updates to KEIP KERP presentation based on internal comments.
9	9/13/2020	Diaz, Matthew	0.9	Participate in a call with the UCC and the Non Debtor states to discuss the proposed KEIP KERP plans.
9	9/13/2020	Diaz, Matthew	0.7	Review of the KERP recommendations and related analysis.
9	9/13/2020	Bromberg, Brian	0.6	Participate in call with UCC advisors and Debtors on KEIP KERP diligence.
9	9/13/2020	Bromberg, Brian	1.0	Review KEIP KERP analysis calculations and performance metrics.
9	9/14/2020	Diaz, Matthew	2.5	Review the updated KEIP KERP comp diligence presentation.
9	9/14/2020	Diaz, Matthew	1.2	Review Willis Towers Watson KEIP KERP benchmarking analysis.
9	9/14/2020	Kim, Ye Darm	1.8	Review UCC analysis of KEIP KERP awards and create analysis of comp calculations.
9	9/14/2020	Kim, Ye Darm	2.2	Process revisions to the KEIP KERP presentation per internal discussion.
9	9/14/2020	Kim, Ye Darm	0.9	Update KEIP KERP presentation to reflect counterproposals.
9	9/14/2020	Kim, Ye Darm	1.0	Participate in call re: revisions to the KEIP KERP diligence presentation.
9	9/14/2020	Kim, Ye Darm	1.9	Process revisions to KEIP KERP diligence presentation.
9	9/14/2020	Kim, Ye Darm	0.9	Process additional revisions to KEIP KERP diligence presentation.
9	9/14/2020	Kim, Ye Darm	1.2	Process additional revisions to KEIP KERP diligence presentation per latest comments.
9	9/14/2020	Bromberg, Brian	2.2	Review and process updates to KEIP KERP presentation based on discussion.
9	9/14/2020	Bromberg, Brian	1.3	Participate in discussion re: KEIP KERP diligence with internal team.
9	9/14/2020	Bromberg, Brian	1.2	Review KEIP KERP supporting diligence materials.
9	9/14/2020	Bromberg, Brian	0.9	Review updated KEIP KERP proposal presentation.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
9	9/14/2020	Bromberg, Brian	2.5	Review and incorporate UCC KEIP KERP proposal into presentation.
9	9/14/2020	Bromberg, Brian	1.6	Process revisions to KEIP KERP diligence presentation.
9	9/15/2020	Diaz, Matthew	0.8	Participate in call with counsel to discuss the proposed employee compensation plans and related recommendations.
9	9/15/2020	Diaz, Matthew	1.6	Perform detailed review and provide revisions for the updated presentation on the KEIP and KERP plans.
9	9/15/2020	Diaz, Matthew	1.9	Perform review of the updated KEIP and KERP plans.
9	9/15/2020	Kim, Ye Darm	2.3	Process updates to KEIP KERP diligence presentation per advisor call.
9	9/15/2020	Kim, Ye Darm	1.0	Participate in discussion with AHC advisors re: KEIP KERP diligence.
9	9/15/2020	Kim, Ye Darm	1.6	Process revisions to the KEIP KERP diligence presentation.
9	9/15/2020	Kim, Ye Darm	0.9	Continue processing revisions to the KEIP KERP diligence presentation.
9	9/15/2020	Kim, Ye Darm	1.1	Review prior year's wage settlement impact to compare with current proposal.
9	9/15/2020	Kim, Ye Darm	0.9	Participate in internal discussion re: KEIP KERP presentation updates per call with advisors.
9	9/15/2020	Kim, Ye Darm	0.3	Participate in internal discussion re: KEIP KERP diligence next steps.
9	9/15/2020	Bromberg, Brian	2.3	Review and provide revisions to KEIP KERP presentation based on latest discussions.
9	9/15/2020	Bromberg, Brian	0.6	Finalize draft KEIP KERP presentation to send to Counsel for discussion.
9	9/15/2020	Bromberg, Brian	0.8	Participate in discussion re: KEIP KERP proposal with Counsel.
9	9/15/2020	Bromberg, Brian	1.0	Discuss KEIP KERP proposal with internal team after discussion with Counsel.
9	9/15/2020	Bromberg, Brian	1.0	Prepare KEIP KERP diligence questions for Debtors.
9	9/16/2020	Diaz, Matthew	0.8	Participate in a call with the AHC professionals to discuss recommendations to the KEIP KERP compensation plans.
9	9/16/2020	Diaz, Matthew	0.6	Participate in a call with the UCC's financial advisors to discuss the proposed KEIP KERP compensation plans.
9	9/16/2020	Diaz, Matthew	1.5	Finalize written materials for the AHC on the proposed KEIP KERP compensation plans.
9	9/16/2020	Kim, Ye Darm	0.8	Process revisions to the KEIP KERP presentation.
9	9/16/2020	Kim, Ye Darm	0.6	Continue processing revisions to the KEIP KERP presentation.
9	9/16/2020	Kim, Ye Darm	0.5	Participate in internal call re: KEIP KERP diligence presentation.
9	9/16/2020	Kim, Ye Darm	2.1	Perform detailed QC of KEIP KERP diligence presentation.
9	9/16/2020	Kim, Ye Darm	0.7	Participate in discussion re: updates to KEIP KERP deck per UCC comments.
9	9/16/2020	Kim, Ye Darm	0.5	Participate in call with AHC advisors re: KEIP KERP presentation.
9	9/16/2020	Bromberg, Brian	2.0	Review newly provided files by Debtors on KEIP KERP diligence.
9	9/16/2020	Bromberg, Brian	2.1	Finalize presentation on KEIP KERP for Committee Call.
9	9/16/2020	Bromberg, Brian	0.7	Discuss KEIP KERP proposal with UCC advisors.
9	9/16/2020	Bromberg, Brian	1.8	Perform detailed QC of KEIP KERP diligence presentation.
9	9/16/2020	Bromberg, Brian	0.7	Discuss diligence questions with Debtors on KEIP and KERP.
9	9/17/2020	Diaz, Matthew	0.3	Draft recommendations to the proposed KEIP KERP compensation plans.
9	9/17/2020	Diaz, Matthew	0.3	Participate in a call with counsel to discuss the AHC recommendations to the proposed employee compensation plans.
9	9/17/2020	Kim, Ye Darm	0.3	Process minor revisions to KEIP KERP presentation before distribution to Counsel.
9	9/17/2020	Bromberg, Brian	0.5	Review latest version of presentation on KEIP KERP diligence.
9	9/18/2020	Diaz, Matthew	0.6	Coordinate and revise proposed joint creditor "ask" re changes to the Debtors' proposed employee compensation plans.
9	9/22/2020	Bromberg, Brian	0.4	Review the latest KERP proposal detail.
9	9/24/2020	Diaz, Matthew	0.8	Participate in a call with key creditor professionals to discuss a coordinate response to the Debtors' propose KEIP/KERP motion.
9	9/24/2020	Diaz, Matthew	0.4	Review of the updated KEIP/KERP proposal.
9	9/24/2020	Diaz, Matthew	0.7	Review the UCC's draft KERP/KEIP objection.
9	9/24/2020	Kim, Ye Darm	0.7	Review UCC draft pleading re: KEIP KERP proposal.
9	9/25/2020	Diaz, Matthew	0.4	Review correspondence on revisions to the proposed KEIP KERP settlements.
9	9/28/2020	Kim, Ye Darm	0.9	Review Counsel's update re: KEIP KERP negotiations, mediation, and injunction extension.
<b>9 Total</b>			<b>147.4</b>	
10	9/3/2020	Bromberg, Brian	0.6	Participate in discussion with Counsel re: tax structure charts.
10	9/4/2020	Bromberg, Brian	0.5	Review tax structure charts sent by Counsel.
10	9/8/2020	Joffe, Steven	2.0	Perform review of latest tax issue documents from Counsel.
10	9/8/2020	Joffe, Steven	0.9	Participate in discussion with Counsel re: latest tax issue documents.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
10	9/8/2020	Bromberg, Brian	0.4	Prepare summary of cash flow projections for tax group.
10	9/8/2020	Bromberg, Brian	0.5	Review tax structuring diagrams presentation.
10	9/8/2020	Bromberg, Brian	0.5	Participate in tax call on post emergence structure.
10	9/9/2020	Joffe, Steven	1.0	Review presentations on tax structuring diagrams and post-emergence structure.
10	9/9/2020	Bromberg, Brian	0.5	Discuss tax considerations on distributable value with team.
10	9/10/2020	Joffe, Steven	0.4	Participate in tax call on post emergence structure.
10	9/10/2020	Bromberg, Brian	0.4	Participate in tax call on post emergence structure.
10	9/17/2020	Joffe, Steven	0.8	Participate in weekly tax call with Counsel.
10	9/17/2020	Bromberg, Brian	0.6	Participate in weekly tax call with Counsel.
10	9/18/2020	Joffe, Steven	0.6	Participate in discussion with team regarding tax stakes in setting up trusts.
10	9/18/2020	Diaz, Matthew	0.5	Review go-forward tax structuring issues.
10	9/18/2020	Kim, Ye Darm	0.9	Update sale proceeds/operational cash flow tax impact analysis.
10	9/18/2020	Kim, Ye Darm	1.5	Prepare tax impact analysis of sale proceeds and operational cash flow.
10	9/18/2020	Kim, Ye Darm	0.8	Process updates to sale proceeds/operational cash flow tax impact analysis.
10	9/18/2020	Kim, Ye Darm	1.0	Update tax impact analysis for untaxed cash flow assumptions.
10	9/18/2020	Kim, Ye Darm	1.1	Process updates to the tax impact analysis for new assumptions.
10	9/18/2020	Bromberg, Brian	0.9	Revise tax impact analysis for new assumptions.
10	9/18/2020	Bromberg, Brian	1.4	Work on creating draft tax impact analysis slide.
10	9/18/2020	Bromberg, Brian	0.6	Discuss trust structure analysis slides with internal team.
10	9/18/2020	Bromberg, Brian	1.3	Review updates and changes to tax impact analysis.
10	9/19/2020	Bromberg, Brian	2.0	Continue reviewing updates and changes to tax impact analysis.
10	9/21/2020	Joffe, Steven	0.5	Discuss tax structuring issues with internal team.
10	9/21/2020	Diaz, Matthew	1.1	Review the trust tax analysis and related presentation to the AHC counsel.
10	9/21/2020	Kim, Ye Darm	0.6	Participate in discussion re: tax impact analysis.
10	9/21/2020	Kim, Ye Darm	1.3	Process revisions to the tax impact analysis per internal discussion.
10	9/21/2020	Bromberg, Brian	0.5	Process revisions and changes to tax impact analysis slide and send to Counsel.
10	9/21/2020	Bromberg, Brian	0.5	Review the trust tax analysis and related slide.
10	9/21/2020	Bromberg, Brian	1.0	Participate in discussion re: tax impact analysis.
10	9/22/2020	Joffe, Steven	0.6	Review of revised tax impact analysis slide and supporting analysis.
10	9/22/2020	Diaz, Matthew	0.5	Review the updated trust tax analysis and related presentation slide.
10	9/22/2020	Kim, Ye Darm	0.6	Participate in internal discussion re: tax impact analysis.
10	9/22/2020	Kim, Ye Darm	0.3	Process revisions to the tax impact analysis slide.
10	9/22/2020	Kim, Ye Darm	0.7	Continue processing revisions to the tax impact analysis slide.
10	9/22/2020	Bromberg, Brian	0.6	Participate in internal discussion re: tax impact analysis.
10	9/22/2020	Bromberg, Brian	1.2	Review updates and revisions to tax impact analysis slides.
10	9/23/2020	Joffe, Steven	0.6	Review presentation from Counsel re: tax issues.
10	9/23/2020	Joffe, Steven	0.8	Participate in weekly Committee call re: tax issues.
10	9/23/2020	Bromberg, Brian	1.1	Review distributable value analysis to process updates to tax impact analysis slide.
10	9/25/2020	Bromberg, Brian	0.3	Review tax commentary re: meeting with Davis Polk.
10	9/30/2020	Joffe, Steven	1.2	Participate in conference call with DPW re: tax impact issues.
<b>10 Total</b>			<b>35.7</b>	
16	9/1/2020	Kim, Ye Darm	1.2	Update distributable value spreadsheet model for additional toggles.
16	9/2/2020	Bromberg, Brian	1.3	Review updated distributable value scenario figures.
16	9/2/2020	Bromberg, Brian	3.7	Review spreadsheet with updated 2020 methodology for distributable value.
16	9/2/2020	Diaz, Matthew	1.9	Review the updated distributable value recovery analysis.
16	9/3/2020	Bromberg, Brian	0.6	Process updates to spreadsheet analysis on distributable value.
16	9/3/2020	Diaz, Matthew	1.2	Review the updated distributable value recovery analysis.
16	9/4/2020	Diaz, Matthew	1.5	Review the updated distributable value recovery analysis.
16	9/4/2020	Diaz, Matthew	0.6	Participate in call with Counsel to discuss the updated distributable value recovery analysis.
16	9/4/2020	Diaz, Matthew	1.2	Review the source materials to the distributable value recovery analysis.
16	9/4/2020	Kim, Ye Darm	0.9	Continue updating distributable value spreadsheet model for revised term sheets.
16	9/4/2020	Kim, Ye Darm	0.4	Update distributable value spreadsheet model based on internal comments.
16	9/8/2020	Diaz, Matthew	0.6	Review the updated distributable value analysis.
16	9/30/2020	Diaz, Matthew	0.7	Develop outline on presentation re: strategic alternatives for distributable value.
16	9/30/2020	Diaz, Matthew	0.6	Participate in a call with Houlihan to discuss presentation to the AHC on strategic alternatives for distributable value.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
16	9/30/2020	Diaz, Matthew	0.9	Participate in a call with Counsel to discuss strategic alternatives in connection with the Sackler mediation.
16	9/30/2020	Bromberg, Brian	1.8	Participate in discussion and outline mediation preparation materials.
<b>16 Total</b>			<b>19.1</b>	
18	9/1/2020	Kurtz, Emma	1.2	Prepare comparison analysis of distributions received from IACs by B Side entities and IAC distributions captured in the IAC cash flow statement.
18	9/1/2020	Bromberg, Brian	1.7	Continue review of Sackler net asset reports and transfers report.
18	9/1/2020	Bromberg, Brian	1.8	Review Sackler net asset reports and transfers report.
18	9/1/2020	Bromberg, Brian	1.4	Review IAC transfers comparison analysis to cash flow statements.
18	9/3/2020	Kurtz, Emma	1.3	Review files received from Counsel re: Sackler B-Side report diligence.
18	9/3/2020	Kurtz, Emma	0.7	Prepare revisions to cash distribution comparison between the IAC financial statements and the Sackler B-Side report.
18	9/3/2020	Bromberg, Brian	0.8	Review IAC historical distributions to Sacklers.
18	9/3/2020	Bromberg, Brian	0.4	Discuss transfers and net assets discovery review with Counsel.
18	9/3/2020	Bromberg, Brian	1.7	Review discovery files produced by Milbank.
18	9/3/2020	Bromberg, Brian	1.4	Compare IAC distributions to IAC cash flow statements.
18	9/9/2020	Kurtz, Emma	0.7	Participate in call with Huron and other advisors to review Sackler B side cash transfers report.
18	9/9/2020	Diaz, Matthew	2.1	Review the Side B model on the historical transfers.
18	9/9/2020	Diaz, Matthew	0.8	Participate in call with Huron to discuss their report on the historical transfers.
18	9/9/2020	Kim, Ye Darm	1.0	Participate in call re: Sackler side B questions.
18	9/9/2020	Bromberg, Brian	1.9	Continue to review supporting model on Side B transfers.
18	9/9/2020	Bromberg, Brian	1.5	Review newly provided model for Side B transfers.
18	9/9/2020	Bromberg, Brian	0.9	Participate in call with Huron re: Side B transfers.
18	9/17/2020	Diaz, Matthew	1.3	Review the historical IAC cash transfers.
18	9/21/2020	Diaz, Matthew	0.9	Review the Side B transfers analysis supporting model.
18	9/21/2020	Bromberg, Brian	1.3	Continue review of the Side B transfers analysis support.
18	9/22/2020	Greenblatt, Matthew	0.5	Prepare summary of observations from review of Alix Partners Transfers Reports.
18	9/22/2020	Diaz, Matthew	1.5	Review the historical cash tracing analysis.
18	9/22/2020	Kim, Ye Darm	1.8	Review analyses of Sackler transfers and assets summaries.
18	9/22/2020	Kim, Ye Darm	1.9	Prepare skeleton presentation re: Sackler asset reports and transfer analyses.
18	9/22/2020	Bromberg, Brian	3.2	Review Sackler net asset reports for Side A and Side B.
18	9/22/2020	Bromberg, Brian	2.8	Prepare outline of Side B Assets and Transfers deck.
18	9/23/2020	Kim, Ye Darm	0.5	Participate in call re: Sackler Assets and Transfers deck workplan.
18	9/23/2020	Kurtz, Emma	1.2	Analyze Raymond side net asset value for initial covered Sackler persons and trusts to tie out the total net asset value.
18	9/23/2020	Kurtz, Emma	1.3	Review net asset reports prepared for the Mortimer and Raymond Sackler sides to evaluate net asset value.
18	9/23/2020	Kurtz, Emma	1.7	Prepare slides re: Sackler net asset reports to include in Sackler assets and transfers update presentation to Committee.
18	9/23/2020	Bromberg, Brian	3.0	Review and process revisions to outline the net asset report and create diligence request list.
18	9/24/2020	Kim, Ye Darm	1.6	Review latest draft of the Sackler assets and transfer presentation.
18	9/24/2020	Kim, Ye Darm	1.8	Review FTI forensic team's workproduct re: reconciliation of cash transfers and excel support.
18	9/24/2020	Kim, Ye Darm	0.9	Update draft Sackler asset and transfers presentation for FTI forensic team workproduct.
18	9/24/2020	Kim, Ye Darm	0.9	Process revisions to the Sackler assets and transfers presentation.
18	9/24/2020	Kurtz, Emma	0.9	Prepare revisions to slides re: Sackler net asset reports.
18	9/24/2020	Bromberg, Brian	0.3	Prepare summary of transfer report analysis call for team.
18	9/24/2020	Bromberg, Brian	1.4	Review draft version of transfers presentation and process revisions.
18	9/24/2020	Bromberg, Brian	2.3	Review Huron reports and backup Excel on historical transfers.
18	9/24/2020	Bromberg, Brian	2.8	Review FTI forensic team workproduct on historical distributions.
18	9/24/2020	Bromberg, Brian	0.6	Participate in call with Huron re: Side B transfers.
18	9/25/2020	Diaz, Matthew	0.6	Review the deposition notes of Theresa Sackler re: historical transfers.
18	9/25/2020	Kim, Ye Darm	1.9	Review Huron's side B reconciliation analysis.
18	9/25/2020	Kim, Ye Darm	1.3	Review historical licensing agreements with Napp Pharmaceutical Holding Ltd.
18	9/25/2020	Kim, Ye Darm	1.3	Continue review of Huron's side-B reconciliation analysis.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
18	9/25/2020	Kurtz, Emma	0.7	Analyze historical licensing agreements to evaluate reasonability of IAC royalty rates.
18	9/25/2020	Bromberg, Brian	1.3	Review and process revisions to Sackler net asset report presentation.
18	9/25/2020	Bromberg, Brian	0.8	Discuss workplan with team re: transfers and net asset diligence.
18	9/25/2020	Bromberg, Brian	3.3	Continue review and processing revisions to Sackler net asset report presentation.
18	9/28/2020	Kim, Ye Darm	1.1	Process revisions to Sackler assets and transfers update presentation.
18	9/28/2020	Kim, Ye Darm	1.9	Process revisions to Sackler asset and transfer presentation.
18	9/28/2020	Bromberg, Brian	1.6	Review latest version of Sackler asset report presentation.
18	9/28/2020	Bromberg, Brian	1.5	Continue review of the latest Sackler asset transfer report presentation.
18	9/29/2020	Greenblatt, Matthew	1.6	Participate in discussions with team re: summary of observations of Alix Partners Cash Report.
18	9/29/2020	Diaz, Matthew	0.9	Review the cash reconciliation analysis re: historical transfers.
18	9/29/2020	Diaz, Matthew	0.4	Review the reconciliation between the Alix report and the Side B report.
18	9/29/2020	Costaldo, Nicole	1.0	Participate in conference with team re: cash distribution reconciliation analysis.
18	9/29/2020	Mazzari, Meredith	0.5	Participate in conference with team re: cash distribution reconciliation analysis.
18	9/29/2020	Mazzari, Meredith	0.4	Participate in call to prepare for meeting re: Reconciliation of AlixPartners Cash Transfers Report
18	9/29/2020	Kyviakidis, Peter	0.5	Participate in conference with team re: cash distribution reconciliation analysis.
18	9/29/2020	Kyviakidis, Peter	0.5	Participate in call to prepare for meeting re: Reconciliation of AlixPartners Cash Transfers Report
18	9/29/2020	Bromberg, Brian	3.7	Process revisions to the historical transfers and net assets presentation.
18	9/29/2020	Bromberg, Brian	0.6	Participate in discussion re: historical cash transfers with internal team.
18	9/30/2020	Bromberg, Brian	2.3	Process revisions to the net asset and historical transfers presentation.
18	9/30/2020	Bromberg, Brian	0.5	Participate in discussion re: historical cash transfers with internal team.
18	9/30/2020	Bromberg, Brian	1.8	Continue review and revisions to the net asset and historical transfers presentation.
<b>18 Total</b>			<b>89.7</b>	
19	9/1/2020	Simms, Steven	0.4	Participate in correspondence on case items re: outstanding workstreams.
19	9/1/2020	Kurtz, Emma	1.0	Participate in internal discussion re: outstanding case items and next steps.
19	9/9/2020	Simms, Steven	0.6	Participate in discussion re: next steps for mediation.
19	9/15/2020	Kurtz, Emma	0.6	Update dataroom index to incorporate recently uploaded documents to share with team.
19	9/18/2020	Bromberg, Brian	1.1	Participate in discussion with team re: outstanding workstreams.
19	9/18/2020	Simms, Steven	0.4	Participate in meeting re: ongoing Purdue workstreams.
19	9/18/2020	Kim, Ye Darm	0.8	Participate in meeting re: ongoing Purdue workstreams.
19	9/18/2020	Kurtz, Emma	1.0	Participate in meeting re: ongoing Purdue workstreams.
19	9/22/2020	Simms, Steven	0.4	Review updates on case issues of current workstreams.
19	9/25/2020	Diaz, Matthew	1.0	Participate in internal call re: IAC business plan update presentation, Sackler assets and transfers update, and additional upcoming deliverables.
19	9/25/2020	Kim, Ye Darm	1.0	Participate in internal call re: IAC business plan update presentation, Sackler assets and transfers update, and additional upcoming deliverables.
19	9/25/2020	Kurtz, Emma	0.7	Participate in internal call re: IAC business plan update presentation, Sackler assets and transfers update, and additional upcoming deliverables.
19	9/28/2020	Kurtz, Emma	1.1	Review recently received dataroom documents to update dataroom index to share with team.
19	9/30/2020	Simms, Steven	0.4	Participate in discussion re: next steps for mediation.
<b>19 Total</b>			<b>10.5</b>	
21	9/3/2020	Bromberg, Brian	1.4	Participate in weekly Committee call re: case updates.
21	9/3/2020	Kim, Ye Darm	1.1	Participate in weekly Committee call re: case updates.
21	9/9/2020	Bromberg, Brian	1.1	Participate in weekly Committee call re: compensation matters.
21	9/9/2020	Diaz, Matthew	1.3	Participate in weekly Committee call re: compensation matters.
21	9/9/2020	Kim, Ye Darm	1.0	Participate in weekly Committee call re: compensation matters.
21	9/16/2020	Bromberg, Brian	1.3	Participate in weekly Committee call re: KEIP KERP issues.
21	9/16/2020	Diaz, Matthew	1.1	Participate in weekly Committee call re: KEIP KERP issues.
21	9/16/2020	Kim, Ye Darm	1.1	Participate in weekly Committee call re: KEIP KERP issues.
21	9/23/2020	Diaz, Matthew	1.2	Participate in weekly Committee call re: go forward mediation with the Sacklers, the employee compensation plans and the IAC current results.
21	9/23/2020	Kim, Ye Darm	1.0	Participate in weekly Committee call re: diligence updates.
21	9/23/2020	Bromberg, Brian	1.2	Participate in weekly Committee call re: IAC performance.
<b>21 Total</b>			<b>12.8</b>	

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
24	9/1/2020	Kim, Ye Darm	3.1	Prepare the July Fee Application.
24	9/1/2020	Kim, Ye Darm	2.2	Review the July Fee Application.
24	9/1/2020	Kim, Ye Darm	2.9	Continue review of the July Fee Application.
24	9/2/2020	Diaz, Matthew	1.4	Review the July bill.
24	9/2/2020	Kim, Ye Darm	1.3	Finalize draft of the July Fee Application.
24	9/2/2020	Kim, Ye Darm	0.8	Process revisions to the draft of the July Fee Application.
24	9/23/2020	Kim, Ye Darm	1.8	Prepare draft of the August fee app.
24	9/23/2020	Kim, Ye Darm	2.0	Prepare exhibits for the August fee app.
24	9/23/2020	Kim, Ye Darm	2.8	Review the August fee app.
24	9/23/2020	Kim, Ye Darm	2.6	Review the August fee app.
24	9/25/2020	Diaz, Matthew	0.7	Review the August bill.
24	9/25/2020	Hellmund-Mora, Marili	0.5	Finalize the July fee application.
24	9/25/2020	Kim, Ye Darm	0.5	Correspond with Counsel re: fee application updates.
24	9/28/2020	Kim, Ye Darm	0.6	Prepare draft August fee application.
24	9/28/2020	Kim, Ye Darm	2.3	Process revisions to August fee app.
<b>24 Total</b>			<b>25.5</b>	
28	9/1/2020	Kurtz, Emma	0.8	Review recently received diligence responses from the Company to evaluate responsiveness to outstanding questions.
28	9/1/2020	Kurtz, Emma	0.4	Update outstanding diligence request list to incorporate responses received from the Company and follow up queries.
28	9/2/2020	Diaz, Matthew	1.3	Review updated IAC due diligence summaries.
28	9/8/2020	Kurtz, Emma	1.1	Prepare updates to dataroom index to incorporate documents recently uploaded to share with team.
28	9/11/2020	Kurtz, Emma	0.7	Review LEK summary report re: assessment of IAC business plan projections.
28	9/11/2020	Bromberg, Brian	1.5	Review newly provided financial model for IACs.
28	9/11/2020	Bromberg, Brian	1.5	Review LEK summary report on the IAC business plan.
28	9/12/2020	Diaz, Matthew	1.6	Review of the updated IAC model received from Mundipharma.
28	9/14/2020	Kurtz, Emma	0.8	Build out summary analysis of product level P&L line items in revised business plan to evaluate impact of top products.
28	9/14/2020	Kurtz, Emma	1.3	Prepare analysis of revised business plan cash flow line items by legal entity.
28	9/14/2020	Kurtz, Emma	1.1	Prepare analysis of revised business plan balance sheet line items by legal entity.
28	9/14/2020	Kurtz, Emma	1.4	Review revised IAC business plan to evaluate changes from June business plan.
28	9/14/2020	Bromberg, Brian	2.6	Review newly provided financial model for IACs.
28	9/15/2020	Kurtz, Emma	1.3	Prepare summary analysis of detailed P&L line items by entity to evaluate information not included in the main P&L tabs.
28	9/15/2020	Kurtz, Emma	1.8	Prepare analysis re: tie out of net income to EBITDA by entity.
28	9/15/2020	Bromberg, Brian	1.4	Continue review of the newly provided financial model for IACs.
28	9/15/2020	Bromberg, Brian	1.2	Review FTI summary analysis of the latest IAC financials.
28	9/16/2020	Diaz, Matthew	1.0	Participate in a call with the CFO of Mundipharma and the other case financial advisors to discuss 6 months 2020 financial performance.
28	9/16/2020	Diaz, Matthew	0.7	Review the presentation materials re: current IAC performance.
28	9/16/2020	Kim, Ye Darm	0.8	Participate in call with IAC CFO re: 2Q20 performance.
28	9/16/2020	Kurtz, Emma	1.9	Prepare analysis re: revised cash flow line items to Steve Jamieson support schedules re: other investing activities, other financing activities, and capital contributions to evaluate differences.
28	9/16/2020	Kurtz, Emma	1.0	Participate in call with Arnaud Breabout, Mundipharma CFO, to discuss 1H 2020 results and risks for 2H 2020.
28	9/16/2020	Kurtz, Emma	1.4	Prepare analysis re: tie out of revised balance sheet line items to Steve Jamieson support schedules re: loans receivable and loans payable.
28	9/16/2020	Kurtz, Emma	1.1	Prepare comparison analysis of revised P&L to Steve Jamieson support schedules re: net interest expense to evaluate differences.
28	9/16/2020	Bromberg, Brian	1.0	Participate in call with Arnaud Breabout, Mundipharma CFO, to discuss 1H 2020 results.
28	9/17/2020	Kim, Ye Darm	0.6	Participate in call re: updated IAC model.
28	9/17/2020	Kurtz, Emma	1.6	Prepare presentation re: IAC 1H 2020 results and risks for 2H 2020 for Committee.
28	9/17/2020	Kurtz, Emma	0.2	Discuss internally re: revised IAC budget, IAC 1H 2020 results, and potential reporting to the Committee.
28	9/17/2020	Kurtz, Emma	1.4	Prepare analysis re: IAC 1H 2020 results to evaluate budget to actual variance.

**EXHIBIT C**  
**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649**  
**DETAIL OF TIME ENTRIES**  
**FOR THE PERIOD SEPTEMBER 1, 2020 TO SEPTEMBER 30, 2020**

<b>Task Category</b>	<b>Date</b>	<b>Professional</b>	<b>Hours</b>	<b>Activity</b>
28	9/17/2020	Bromberg, Brian	3.3	Create initial diligence questions list on new IAC model.
28	9/17/2020	Bromberg, Brian	0.5	Discuss updated IAC model summary slides with team.
28	9/17/2020	Bromberg, Brian	2.5	Review the FTI summary analysis of the latest IAC model.
28	9/17/2020	Bromberg, Brian	1.3	Review prior IAC diligence responses to prepare new request list.
28	9/18/2020	Diaz, Matthew	1.1	Review of updated IAC financials summary analysis and discuss related next steps.
28	9/18/2020	Kim, Ye Darm	0.9	Process revisions to the IAC 1H20 performance summary slides.
28	9/18/2020	Kim, Ye Darm	1.6	Process revisions to the IAC 1H20 performance summary slides.
28	9/18/2020	Kim, Ye Darm	1.0	Review IAC 1H20 performance summary slides.
28	9/18/2020	Kurtz, Emma	0.4	Prepare updates to the IAC diligence request list to incorporate questions surrounding the revised IAC business plan.
28	9/18/2020	Kurtz, Emma	0.4	Prepare revisions to analysis re: revised IAC budget to incorporate internal comments.
28	9/18/2020	Bromberg, Brian	2.4	Review and process revisions to the IAC diligence update slides.
28	9/21/2020	Diaz, Matthew	1.2	Review the updated IAC diligence analysis.
28	9/21/2020	Diaz, Matthew	0.9	Review the presentation to the AHC on the IAC year to date performance.
28	9/21/2020	Kim, Ye Darm	0.9	Review diligence responses for product data provided by IACs.
28	9/21/2020	Kim, Ye Darm	1.2	Process updates to IAC 1H20 performance summary slides per internal comments.
28	9/21/2020	Bromberg, Brian	1.8	Review IAC diligence materials provided in dataroom.
28	9/21/2020	Bromberg, Brian	1.5	Finalize draft of IAC update to send to Houlihan Lokey.
28	9/22/2020	Diaz, Matthew	1.1	Review the LEK report on the IAC business plan.
28	9/22/2020	Diaz, Matthew	0.9	Participate in a call with Houlihan to discuss the IAC presentation to the AHC.
28	9/22/2020	Kim, Ye Darm	0.6	Participate in call re: IAC financial update presentation.
28	9/22/2020	Kurtz, Emma	0.8	Participate in call with Houlihan to discuss IAC update presentation to Committee.
28	9/22/2020	Bromberg, Brian	0.5	Participate in discussion re: IAC updates with Houlihan Lokey.
28	9/22/2020	Bromberg, Brian	1.2	Finalize the IAC update deck to send to Counsel.
28	9/23/2020	Bromberg, Brian	2.2	Review IAC provided materials on new product forecasts.
28	9/23/2020	Bromberg, Brian	0.5	Work on clearance for IAC update deck to the Committee.
28	9/24/2020	Bromberg, Brian	0.8	Review the IAC financial support materials provided in the dataroom.
28	9/25/2020	Diaz, Matthew	0.6	Review the agenda for the DB call re: IAC sale process.
28	9/25/2020	Kurtz, Emma	0.4	Prepare updates to outstanding diligence request list to reflect recent responses and additional requests re: revised business plan.
28	9/25/2020	Bromberg, Brian	0.9	Create diligence question list for call with Deutsche Bank re: IAC sale process.
28	9/28/2020	Kim, Ye Darm	0.5	Review topic list for call with Deutsche Bank re: IAC sale process.
28	9/28/2020	Kim, Ye Darm	1.9	Review latest IAC financial model provided by Huron.
28	9/28/2020	Kurtz, Emma	1.4	Review revised business plan model to evaluate follow up questions for Steve Jamieson.
28	9/28/2020	Bromberg, Brian	1.9	Create outline of IAC presentation based on new diligence information.
28	9/29/2020	Diaz, Matthew	0.9	Review the updated IAC due diligence materials.
28	9/29/2020	Kurtz, Emma	2.2	Prepare analysis of revised budget product P&L to evaluate changes to financial projections.
28	9/29/2020	Bromberg, Brian	1.6	Review newly provided product-level files from IACs.
28	9/30/2020	Bromberg, Brian	0.5	Prepare revised question list for Deutsche Bank re: IAC sale process.
28	9/30/2020	Bromberg, Brian	2.2	Review of the worldwide product P&L files re: IAC forecasts.
<b>28 Total</b>			<b>81.0</b>	
<b>Grand Total</b>			<b>471.8</b>	